ERBB2 and neoplasm: Inhibition of ErbB2-dependent proliferation of 32D_B2/B3 cells as well as inhibition of ErbB2-expressing tumor cell growth by ST8176AA1 was higher than that obtained with trastuzumab as measured by CellTiter-Glo Luminescent Cell Viability assay (Table 1).